Mizuho Securities Remains a Buy on Adverum Biotechnologies (ADVM)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities' analyst Graig Suvannavejh maintains a Buy rating on Adverum Biotechnologies with a price target of $5.50. Suvannavejh, who covers the Healthcare sector, has an average return of 12.2% and a 50.43% success rate. The analyst consensus on Adverum Biotechnologies is a Moderate Buy with an average price target of $9.90.
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Adverum Biotechnologies, with a price target of $5.50.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Suvannavejh covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Immuneering, and Harmony Biosciences Holdings. According to TipRanks, Suvannavejh has an average return of 12.2% and a 50.43% success rate on recommended stocks.
Currently, the analyst consensus on Adverum Biotechnologies is a Moderate Buy with an average price target of $9.90.